Affimed stock plunges 23% on AFM24 study update
by
Contributor since / Followers
Contributor since / Followers
5 days ago
Michail_Petrov-96 Shares of Affimed (NASDAQ:AFMD) plunged 23% in early trading Tuesday after the company reported
AFMD
Affimed reports data from mid-stage study of its lymphoma treatment
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
Affimed N.V. announced data from phase 2 study of the combination of acimtamig with Artiva
Affimed GAAP EPS of -€0.94, revenue of €0.16M
by
Contributor since / Followers
Contributor since / Followers
1 month ago
Affimed press release (NASDAQ:AFMD): Q3 GAAP EPS of -€0.94. Revenue of €0.16M (-91.8% Y/Y). As
Affimed Q3 2024 Earnings Preview
by
Contributor since / Followers
Contributor since / Followers
1 month ago
Affimed (NASDAQ:AFMD) is scheduled to announce Q3 earnings results on Thursday, November 14th, before market
Affimed files for $20M mixed securities shelf
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Affimed (NASDAQ:AFMD) filed for $20M mixed securities shelf. This preliminary prospectus is not an offer
Affimed GAAP EPS of -€1.01, revenue of €0.2M
by
Contributor since / Followers
Contributor since / Followers
4 months ago
Affimed press release (NASDAQ:AFMD): Q2 GAAP EPS of -€1.01. Revenue of €0.2M (-85.7% Y/Y). As of
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
by Pivotal Biotech
Contributor since 2024 / 357 Followers
Contributor since 2024 / 357 Followers
4 months ago
Summary: On 06/11/24, I published an article on Affimed focused on my belief the company’s
Affimed appoints Shawn Leland as chief executive officer
by
Contributor since / Followers
Contributor since / Followers
4 months ago
Affimed N.V. (NASDAQ:AFMD) has announced that Shawn M. Leland, PharmD, RPh has been appointed as Chief
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial
by
Contributor since / Followers
Contributor since / Followers
6 months ago
Hailshadow Shares of Affimed (NASDAQ:AFMD) gained in the premarket on Wednesday after the German biotech
Affimed reports Q1 results
by
Contributor since / Followers
Contributor since / Followers
6 months ago
Affimed press release (NASDAQ:AFMD): Q1 total revenue was €0.2 million compared with €4.5 million for